Beta Blockers in Hypertension

Comprehensive Hypertension

Volumn , Issue , 2007, Pages 959-970

  Panjrath, Gurusher S ^a   Messerli, Franz H ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b St Lukes Roosevelt Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052239761     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03961-1.50081-7     Document Type: Chapter

References (103)

1. BN Prichard and PM Gillam (1964) Use of propranolol (inderal) in treatment of hypertension. Br Med J 5411 725-727.
2. AV Chobanian, GL Bakris, HR Black, et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289(19), 2560-2572.
3. AV Chobanian, GL Bakris, HR Black, et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252.
4. RJ Lefkowitz, MG Caron and GL Stiles (1984) Mechanisms of membrane-receptor regulation: Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. N Engl J Med 310(24), 1570-1579.
5. AM Lands, A Arnold, JP McAuliff, et al. (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214(88), 597-598.
6. KP Minneman, A Hedberg and PB Molinoff (1979) Comparison of beta adrenergic receptor subtypes in mammalian tissues. J Pharmacol Exp Ther 211(3), 502-508.
7. A Hedberg, KP Minneman and PB Molinoff (1980) Differential distribution of beta-1 and beta-2 adrenergic receptors in cat and guinea-pig heart. J Pharmacol Exp Ther 212(3), 503-508.
8. JM Cruickshank (1994) Beta Blockers in Clinical Practice, Second Edition Edinburgh: Churchill-Livingstone 1-1204.
9. HT Colfer, C Cottier, R Sanchez and S Julius (1984) Role of cardiac factors in the initial hypotensive action by beta-adrenoreceptor blocking agents. Hypertension 6(2/1), 145-151.
10. AJ Man In't Veld and MA Schalekamp (1983) Effects of 10 different beta-adrenoceptor antagonists on hemodynamics, plasma renin activity, and plasma norepinephrine in hypertension: The key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol 5(1), S30-S45.
11. FR Buhler, JH Laragh, L Baer, et al. (1972) Propranolol inhibition of renin secretion: A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 287(24), 1209-1214.
12. J Castenfors, H Johnsson and L Oro (1973) Effect of alprenolol on blood pressure and plasma renin activity in hypertensive patients. Acta Med Scand 193(3), 189-195.
13. L Hansson (1973) Beta-adrenergic blockade in essential hypertension: Effects of propranolol on hemodynamic parameters and plasma renin activity. Acta Med Scand Suppl 550 1-40.
14. AM Richards, MG Nicholls, EA Espiner, et al. (1986) Diurnal patterns of blood pressure, heart rate and vasoactive hormones in normal man. Clin Exp Hypertens A 8(2), 153-166.
15. HH Vincent, AJ Man In't Veld, F Boomsma, et al. (1982) Elevated plasma noradrenaline in response to beta-adrenoceptor stimulation in man. Br J Clin Pharmacol 13(5), 717-721.
16. B Dahlof, L Andren, A Svensson and L Hansson (1983) Antihypertensive mechanism of beta-adrenoceptor antagonism: The role of beta 2-blockade. J Hypertens Suppl 1(2), 112-115.
17. DC Fitzgerald (1984) Beta-adrenoceptor antagonism. PA van Zwieten (Eds) Pharmacology of antihypertensive drugs 3 Amsterdam: Elsevier 249-306. ( Handbook of hypertension,.)
18. ME Conolly, F Kersting and CT Dollery (1976) The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis 19(3), 203-234.
19. W Frishman (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1: Pharmacodynamic and pharmacokinetic properties. Am Heart J 97(5), 663-670.
20. J Koch-Weser and WH Frishman (1981) Beta-adrenoceptor antagonists: New drugs and new indications. N Engl J Med 305(9), 500-506.
21. BN Singh, P Deedwania, K Nademanee, et al. (1987) Sotalol: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 34(3), 311-349.
22. W McNeely and KL Goa (1999) Nebivolol in the management of essential hypertension: A review. Drugs 57(4), 633-651.
23. LHSE Opie, WH Frishman, et al. (1995) Beta blocking agents. LH Opie, WH Frishman, et al., (Eds) Drugs for the Heart, Fourth Edition Philadelphia: W. B. Saunders 1-30.
24. DG McDevitt (1987) Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur Heart J 8(M), 9-14.
25. JM Cruickshank (1980) The clinical importance of cardioselectivity and lipophilicity in beta blockers. Am Heart J 100(2), 160-178.
26. DG McDevitt (1986) Pharmacological characteristics of beta blockers and their role in clinical practice. J Cardiovasc Pharmacol 8(6), S5-11.
27. U Borchard (1990) Pharmacokinetics of beta-adrenoceptor blocking agents: Clinical significance of hepatic and/or renal clearance. Clin Physiol Biochem 8(2), 28-34.
28. G Johnsson and CG Regardh (1976) Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet 1(4), 233-263.
29. DG Shand (1974) Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs 7(1), 19-47.
30. F Galletti, ML Fasano, LA Ferrara, et al. (1989) Obesity and beta blockers: Influence of body fat on their kinetics and cardiovascular effects. J Clin Pharmacol 29(3), 212-216.
31. BN Prichard (1987) Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs. Am J Cardiol 59(13), 13F-17F.
32. GR Hart and RJ Anderson (1981) Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med 141(9), 1125-1127.
33. PA Routledge and DG Shand (1979) Clinical pharmacokinetics of propranolol. Clin Pharmacokinet 4(2), 73-90.
34. E Mutschler, H Spahn and W Kirch (1984) The interaction between H2-receptor antagonists and beta-adrenoceptor blockers. Br J Clin Pharmacol 17(1), 51S-57S.
35. ML Beckmann, JG Gerber, RL Byyny, et al. (1988) Propranolol increases prostacyclin synthesis in patients with essential hypertension. Hypertension 12(6), 582-588.
36. SE Warren, E Ebert, AH Swerdlin, et al. (1979) Clonidine and propranolol paradoxical hypertension. Arch Intern Med 139(2), 253.
37. C Vernon and A Sakula (1979) Fatal rebound hypertension after abrupt withdrawal of clonidine and propranolol. Br J Clin Pract 33(4), 112. 121
38. MC Houston and R Hodge (1988) Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 116(2/1), 515-523.
39. BM Psaty, TD Koepsell, EH Wagner, et al. (1990) The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 263(12), 1653-1657.
40. JM Cruickshank (2000) Beta blockers continue to surprise us. Eur Heart J 21(5), 354-364.
41. P Weidmann, C Ferrier, H Saxenhofer, et al. (1988) Serum lipoproteins during treatment with antihypertensive drugs. Drugs 35(6), 118-134.
42. RH Grimm Jr (1991) Antihypertensive therapy: Taking lipids into consideration. Am Heart J 122(3/2), 910-918.
43. WC Roberts (1989) Recent studies on the effects of beta blockers on blood lipid levels. Am Heart J 117(3), 709-714.
44. BL Kasiske, JZ Ma, RS Kalil and TA Louis (1995) Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122(2), 133-141.
45. AM Sharma, T Pischon, S Hardt, et al. (2001) Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension 37(2), 250-254.
46. J Chen, MJ Radford, Y Wang, et al. (2001) Effectiveness of beta blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 37(7), 1950-1956.
47. Medical Research Council Working Party on Mild to Moderate Hypertension. (1981) Adverse reactions to bendrofluazide and propranolol for the treatment of mild. Hypertension 2(8246), 539-543.
48. FH Messerli and E Grossman (2002) Beta blocker therapy and depression. JAMA 288(15), 1845-1846.
49. SA Salem and DG McDevitt (1983) Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther 33(1), 52-57.
50. FH Messerli and E Grossman (2004) Beta blockers in hypertension: Is carvedilol different? Am J Cardiol 93(9A), 7B-12B.
51. B Charney, BR Meyer, WH Frishman, et al. (1997) Gender, race, and genetic issues in cardiovascular pharmacotherapeutics. WH Frishman (Eds) Cardiovascular Pharmacotherapeutics New York: McGraw Hill 1347-1361.
52. JA Johnson, BS Burlew and RN Stiles (1995) Racial differences in beta-adrenoceptor-mediated responsiveness. J Cardiovasc Pharmacol 25(1), 90-96.
53. HH Zhou, RP Koshakji, DJ Silberstein, et al. (1989) Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 320(9), 565-570.
54. PA Poole-Wilson, K Swedberg, JG Cleland, et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET) randomised controlled trial. Lancet 362(9377), 7-13.
55. The beta blocker heart attack trial (1981) Beta blocker Heart Attack Study Group. JAMA 246(18), 2073-2074.
56. TR Pedersen (1983) The Norwegian Multicenter Study of Timolol after Myocardial Infarction. Circulation 67(6/2), 149-153.
57. HJ Dargie (2001) Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 357(9266), 1385-1390.
58. A randomized trial of propranolol in patients with acute myocardial infarction. (1983) II. Morbidity results. JAMA 250(20), 2814-2819.
59. SS Gottlieb, RJ McCarter and RA Vogel (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339(8), 489-497.
60. H Mickley, H Eiskjaer and HE Botker (2004) Is an additional post-myocardial infarction beta blocker trial required in the era of early revascularization? Eur Heart J 25(1), 96-97.
61. Metoprolol in acute myocardial infarction: Mortality. The MIAMI Trial Research Group. Am J Cardiol 56(14), 15G-22G.
62. Metoprolol in acute myocardial infarction (MIAMI) (1985) A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J 6(3), 199-226.
63. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction (1986) ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2(8498), 57-66.
64. ZM Chen, HC Pan, YP Chen, et al. (2005) Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 366(9497), 1622-1632.
65. ET Skarfors, HO Lithell, I Selinus and H Aberg (1989) Do antihypertensive drugs precipitate diabetes in predisposed men? BMJ 298(6681), 1147-1152.
66. C Bengtsson, G Blohme, L Lapidus, et al. (1992) Diabetes incidence in users and non-users of antihypertensive drugs in relation to serum insulin, glucose tolerance and degree of adiposity: A 12-year prospective population study of women in Gothenburg, Sweden. J Intern Med 231(6), 583-588.
67. T Pollare, H Lithell, I Selinus and C Berne (1989) Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 298(6681), 1152-1157.
68. H Lithell, T Pollare and B Vessby (1992) Metabolic effects of pindolol and propranolol in a double-blind crossover study in hypertensive patients. Blood Press 1(2), 92-101.
69. B Dahlof, RB Devereux, SE Kjeldsen, et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359(9311), 995-1003.
70. UK Prospective Diabetes Study Group. (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317(7160), 713-720.
71. JM Cruickshank (2002) Beta blockers and diabetes: The bad guys come good. Cardiovasc Drugs Ther 16(5), 457-470.
72. J Kjekshus, E Gilpin, G Cali, et al. (1990) Diabetic patients and beta blockers after acute myocardial infarction. Eur Heart J 11(1), 43-50.
73. GL Bakris, V Fonseca, RE Katholi, et al. (2004) Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 292(18), 2227-2236.
74. B Folkow (1982) Physiological aspects of primary hypertension. Physiol Rev 62(2), 347-504.
75. EG Lakatta and D Levy (2003) Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: Aging arteries: a “setup” for vascular disease. Circulation 107(1), 139-146.
76. FH Messerli, K Sundgaard-Riise, HO Ventura, et al. (1983) Essential hypertension in the elderly: Haemodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 2(8357), 983-986.
77. P Lund-Johansen and P Ormvik (1995) Hemodynamic patterns of untreated hypertensive disease. JHBB Laragh (Eds) Hypertension: Pathophysiology, Diagnosis, and Management, Second Edition New York: Raven Press 323-342.
78. NK Hollenberg, M Epstein, RI Basch and JP Merrill (1969) “No man's land” of the renal vasculature: An arteriographic and hemodynamic assessment of the interlobar and arcuate arteries in essential and accelerated hypertension. Am J Med 47(6), 845-854.
79. GM London, ME Safar, JE Sassard, et al. (1984) Renal and systemic hemodynamics in sustained essential hypertension. Hypertension 6(5), 743-754.
80. RE Schmieder, H Schachinger and FH Messerli (1994) Accelerated decline in renal perfusion with aging in essential hypertension. Hypertension 23(3), 351-357.
81. DD Maki, JZ Ma, TA Louis and BL Kasiske (1995) Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155(10), 1073-1080.
82. BL Kasiske, RS Kalil, JZ Ma, et al. (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118(2), 129-138.
83. CE Mogensen (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310(6), 356-360.
84. K Weber, T Bohmeke, R van der Does and SH Taylor (1996) Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 10(2), 113-117.
85. AJ Man In't Veld, AH Van den Meiracker and MA Schalekamp (1988) Do beta blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. Am J Hypertens 1(1), 91-96.
86. P Lund-Johansen (1979) Hemodynamic consequences of long-term beta blocker therapy: A 5-year follow-up study of atenolol. J Cardiovasc Pharmacol 1(5), 487-495.
87. JH Bauer (1994) Diabetic nephropathy: Can it be prevented? Are there renal protective antihypertensive drugs of choice? South Med J 87(10), 1043-1053.
88. JH Bauer and CS Brooks (1979) The long-term effect of propranolol therapy on renal function. Am J Med 66(3), 405-410.
89. EL Schiffrin, LY Deng and P Larochelle (1995) Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor: Comparison with effects of a beta blocker. Am J Hypertens 8(3), 229-236.
90. EL Schiffrin, LY Deng and P Larochelle (1994) Effects of a beta blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23(1), 83-91.
91. FH Messerli, E Grossman and U Goldbourt (1998) Are beta blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 279(23), 1903-1907.
92. AU Klingbeil, M Schneider, P Martus, et al. (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115(1), 41-46.
93. SP Schulman, JL Weiss, LC Becker, et al. (1990) The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 322(19), 1350-1356.
94. EL Schiffrin, JB Park, HD Intengan and RM Touyz (2000) Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101(14), 1653-1659.
95. E Grossman and FH Messerli (2002) Why beta blockers are not cardioprotective in elderly patients with hypertension. Curr Cardiol Rep 4(6), 468-473.
96. GYH Lip and A Tello-Montoliu (2006) Management of atrial fibrillation. Heart 92 1177-1182.
97. S Lewington, R Clarke, N Qizilbash, et al. (2002) Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360(9349), 1903-1913.
98. AW Haider, MG Larson, SS Franklin and D Levy (2003) Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138(1), 10-16.
99. RS Vasan and D Levy (1996) The role of hypertension in the pathogenesis of heart failure: A clinical mechanistic overview. Arch Intern Med 156(16), 1789-1796.
100. MJ Klag, PK Whelton, BL Randall, et al. (1997) End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 277(16), 1293-1298.
101. S MacMahon, R Peto, J Cutler, et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet 335(8692), 765-774.
102. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981-2997.
103. B Carlberg, O Samuelsson and LH Lindholm (2004) Atenolol in hypertension: is it a wise choice? Lancet 364(9446), 1684-1689.